Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 5, 2010, Pages 1977-1982

  Wong, Yuan Qi ^a   Binger, Katrina J ^a,b   Howlett, Geoffrey J ^a   Griffin, Michael D W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSIRO   (Australia)

Author keywords

Aggregation; Amyloidosis; Atherosclerosis; Protein misfolding

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; CONGO RED; METHIONINE; TETRAMER; THIOFLAVINE;

ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; MELTING POINT; OXIDATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMOSTABILITY; ULTRACENTRIFUGATION;

AMYLOID; APOLIPOPROTEIN A-I; CRYSTALLOGRAPHY, X-RAY; HUMANS; METHIONINE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; OXIDATION-REDUCTION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; THERMODYNAMICS; THIAZOLES;

EID: 76649124599     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910136107     Document Type: Article

References (49)

1. Barter PJ, et al. (2004) Antiinflammatory properties of HDL. Circ Res, 95(8):764-772.
2. Rye KA, Barter PJ (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol, 24(3):421-428.
3. Saito H, Lund-Katz S, Phillips MC (2004) Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res, 43(4):350-380.
4. Gregorini G, et al. (2005) Renal apolipoprotein A-I amyloidosis: A rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol, 16(12): 3680-3686.
5. Obici L, et al. (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid, 13(4):191-205.
6. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K (1995) Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol, 147(5): 1186-1192.
7. Mucchiano GI, Haggqvist B, Sletten K, Westermark P (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol, 193(2): 270-275.
8. Mucchiano GI, Jonasson L, Haggqvist B, Einarsson E, Westermark P Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol, 115(2):298-303.
9. Rocken C, et al. (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol, 26(3):676-677.
10. Howlett GJ, Moore KJ (2006) Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol, 17(5):541-547.
11. Medeiros LA, et al. (2004) Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem, 279(11):10643-10648.
12. Moore KJ, et al. (2002) A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem, 277(49):47373-47379.
13. Buxbaum JN (2004) The systemic amyloidoses. Curr Opin Rheumatol, 16(1):67-75.
14. Andreola A, et al. (2003) Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem, 278(4):2444-2451.
15. Booth DR, et al. (1995) A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM, 88(10):695-702.
16. Booth DR, et al. (1996) Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest, 97(12): 2714-2721.
17. Soutar AK, et al. (1992) ApolipoproteinAImutation Arg-60 causes autosomal dominant amyloidosis. P Natl Acad Sci USA, 89(16):7389-7393.
18. Pankhurst G, et al. (2003) Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res, 44(2):349-355.
19. Sigalov AB, Stern LJ (2001) Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids, 113(1-2):133-146.
20. Brock JW, et al. (2008) Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res, 49(4):847-855.
21. Zheng L, et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 114(4):529-541.
22. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. P Natl Acad Sci USA, 105(34):12224-12229.
23. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R (1998) Oxidation of high density lipoproteins II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem, 273(11):6088-6095.
24. Nicholls SJ, Zheng L, Hazen SL (2005) Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovas Med, 15(6):212-219.
25. Gursky O, Atkinson D (1996) Thermal unfolding of human high-density apolipoprotein A-1: Implications for a lipid-free molten globular state. P Natl Acad Sci USA, 93(7):2991-2995.
26. Vitello LB, Scanu AM (1976) Studies on human serum high density lipoproteins Self-association of apolipoprotein A-I in aqueous solutions. J Biol Chem, 251(4):1131-1136.
27. Griffin MD, et al. (2008) Phospholipid interaction induces molecular-level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. J Mol Biol, 375(1):240-256.
28. Hatters DM, MacPhee CE, Lawrence LJ, Sawyer WH, Howlett GJ (2000) Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops. Biochemistry, 39(28):8276-8283.
29. Sunde M, et al. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol, 273(3):729-739.
30. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: An overview. Free Radical Bio Med, 28(12):1815-1826.
31. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med, 340(2):115-126.
32. Panzenbock U, Stocker R (2005) Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta, 1703(2):171-181.
33. Woodward M, et al. (2009) Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci, 116(1):53-60.
34. Hou L, Kang I, Marchant RE, Zagorski MG (2002) Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. J Biol Chem, 277(43):40173-40176.
35. Breydo L, et al. (2005) Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation. Biochemistry, 44(47):15534-15543.
36. Maleknia SD, Reixach N, Buxbaum JN (2006) Oxidation inhibits amyloid fibril formation of transthyretin. Febs J, 273(23):5400-5406.
37. Uversky VN, et al. (2002) Methionine oxidation inhibits fibrillation of human alphasynuclein in vitro. FEBS Lett, 517(1-3):239-244.
38. Binger KJ, Griffin MD, Howlett GJ (2008) Methionine oxidation inhibits assembly and promotes disassembly of apolipoprotein C-II amyloid fibrils. Biochemistry, 47(38):10208-10217.
39. Kelly JW, et al. (1997) Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem, 50:161-181.
40. Nielsen L, et al. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry, 40(20):6036-6046.
41. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM (2006) Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. P Natl Acad Sci USA, 103(7):2126-2131.
42. Hung A, Griffin MD, Howlett GJ, Yarovsky I Effects of oxidation, pH and lipids on amyloidogenic peptide structure: Implications for fibril formation?. Eur Biophys J, 38(1):99-110.
43. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B (1995) Conformational mimicry in Alzheimer's disease Role of apolipoproteins in amyloidogenesis. Am J Pathol, 147(2):238-244.
44. Mangione P, et al. (2001) Amyloid fibrils derived from the apolipoprotein A1 Leu174-Ser variant contain elements of ordered helical structure. Protein Sci, 10(1):187-199.
45. Westermark P, Sletten K, Johnson KH (1996) Ageing and amyloid fibrillogenesis: Lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide. Ciba F Symp, 199:205-218 discussion 218-222.
46. Westermark P, Westermark GT (2005) Purification of transthyretin and transthyretin fragments from amyloid-rich human tissues. Methods Mol Biol, 299:255-260.
47. Relini A, et al. (2004) Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: An atomic force microscopy study. Biochim Biophys Acta, 1690(1):33-41.
48. Anantharamaiah GM, et al. (1988) Effect of oxidation on the properties of apolipo-proteins A-I and A-II. J Lipid Res, 29(3):309-318.
49. Brown PH, Schuck P (2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J, 90(12):4651-4661.